1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,051 | 0,209 | 16:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ExpreS2ion Biotech Holding AB: ExpreS2ion Reports Positive DSMB Outcome and Expanded Preliminary Phase I Data for ES2B-C001 | 206 | GlobeNewswire (Europe) | Hørsholm, Denmark, 12 August 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel immunotherapies... ► Artikel lesen | |
| 25.06. | ExpreS2ion Biotech Holding AB: Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 25 June 2026 | 273 | GlobeNewswire (Europe) | Helsingborg, Sweden, 25 June 2026 - The Annual General Meeting 2026 (the "AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 25 June 2026. The notice to convene... ► Artikel lesen | |
| 01.06. | ExpreS2ion Biotech Holding AB: ExpreS2ion reviews Q1 progress across clinical, operational and financial fronts | 189 | GlobeNewswire (Europe) | Hørsholm, Denmark, 1 June 2026 - ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") reviews its Q1 2026 progress across clinical, operational and financial fronts... ► Artikel lesen | |
| 28.05. | ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Quarter of 2026 | 455 | GlobeNewswire (Europe) | Hørsholm, Denmark, 28 May 2026 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or "the Company") today announces its first quarter 2026 results. The report is available as an attachment and on ExpreS2ion's... ► Artikel lesen | |
| 19.05. | ExpreS2ion Biotech Holding AB: ExpreS2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations | 217 | GlobeNewswire (Europe) | Hørsholm, Denmark, 19 May 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel immunotherapies... ► Artikel lesen | |
| EXPRES2ION BIOTECH Aktie jetzt für 0€ handeln | |||||
| 04.05. | ExpreS2ion Biotech Holding AB: ExpreS2ion announces final outcome of its rights issue of units | 240 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 15.04. | Listing of units rights and paid subscription units of ExpreS2ion Biotech Holding AB | 223 | GlobeNewswire | With effect from April 16, 2026, the units rights in ExpreS2ion Biotech Holding AB will be traded on First North Growth Market. Trading will continue up until and including April 27, 2026.
... ► Artikel lesen | |
| 14.04. | ExpreS2ion Biotech Holding AB: ExpreS2ion publishes prospectus in connection with SEK 53 million rights issue to complete Phase I and support partnering activities | 232 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 13.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026 | 209 | Xetra Newsboard | Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen | |
| 07.04. | ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead cancer program, and publishes terms for the rights issue | 831 | GlobeNewswire (Europe) | Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by... ► Artikel lesen | |
| 01.04. | ExpreS2ion Biotech Holding AB: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 1 April 2026 | 237 | GlobeNewswire (Europe) | Hørsholm, Denmark, 1 April 2026 - Today, on 1 April 2026, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting (the "EGM"). The notice to convene the... ► Artikel lesen | |
| 25.03. | ExpreS2ion Biotech Holding AB: ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review | 232 | GlobeNewswire (Europe) | Hørsholm, Denmark, 25 March 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active immunotherapy... ► Artikel lesen | |
| 27.02. | Expres2ion Biotech Holding AB: Expres2ion Announces The Board Of Directors' Intention To Resolve On A Rights Issue Of Units Of Approximately Sek 53 Million | 533 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 19.02. | ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the Full-Year and Fourth Quarter of 2025 | 419 | GlobeNewswire (Europe) | Hørsholm, Denmark, 19 February 2026 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its full-year and fourth quarter 2025 results. The report is available as an attachment and on ExpreS2ion's... ► Artikel lesen | |
| 03.02. | ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech announces Redeye initiation of coverage with base case valuation of SEK 28 per share | 198 | GlobeNewswire (Europe) | Hørsholm, Denmark, 3 February 2026 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") today announces that Redeye has initiated equity research coverage of ExpreS2ion. In its initiation... ► Artikel lesen | |
| 03.02. | ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial of ES2B-C001 | 429 | GlobeNewswire (Europe) | Hørsholm, Denmark, 03 February 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine... ► Artikel lesen | |
| 28.01. | ExpreS2ion Biotech Holding AB: As Nipah Virus Outbreaks in India Re-emerge, ExpreS2ion Selects Northway Biotech as Manufacturing Partner for Vaccine Program | 459 | GlobeNewswire (Europe) | Hørsholm, Denmark, 28 January 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine... ► Artikel lesen | |
| 13.11.25 | ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025 | 359 | GlobeNewswire (Europe) | Hørsholm, Denmark, 13 November 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its first nine months and third quarter 2025 results. The report is available as an attachment and... ► Artikel lesen | |
| 04.09.25 | ExpreS2ion Biotech Holding AB: ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial | 293 | GlobeNewswire (Europe) | Hørsholm, Denmark, 4 September 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine... ► Artikel lesen | |
| 21.08.25 | ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303 | 231 | GlobeNewswire (Europe) | Hørsholm, Denmark, 21 August 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion" or the "Company") is pleased to announce that Pareto Securities has published... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | 0,00 % | Moderna-Aktie: Plötzlich deutlich besser als BioNTech | Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute... ► Artikel lesen | |
| EVOTEC | 3,446 | -2,87 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| BB BIOTECH | 56,30 | 0,00 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,005 | +4,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,290 | -0,98 % | Qiagen-Aktie: Jetzt auf Fünfmonatshoch - lohnt sich der Einstieg? | Qiagen-Aktien legen heute kräftig zu. An der Frankfurter Börse kletterten die Papiere des Diagnostikspezialisten um 4 Prozent nach oben und markierten damit den höchsten Stand seit fünf Monaten. Der... ► Artikel lesen | |
| MODERNA | 54,61 | -0,20 % | Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly | ||
| VALNEVA | 3,061 | -0,33 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| NOVAVAX | 6,950 | -0,14 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,510 | +0,40 % | Heidelberg Pharma: Was die Halbjahreszahlen über die Zukunft verraten | Bei Biotech-Unternehmen sagt eine einzelne Zahlenreihe selten alles, doch manchmal markiert sie einen Wendepunkt. Bei der Heidelberg Pharma AG (ISIN: DE000A11QVV0) könnte der Mitte Juli vorgelegte Halbjahresbericht... ► Artikel lesen | |
| NANOREPRO | 1,925 | 0,00 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.08.2026 / 07:15... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,640 | +1,69 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BRAIN BIOTECH | 2,740 | -2,49 % | Brain Biotech: Sven K. Weber wird neuer Vorstandsvorsitzender | Der Aufsichtsrat der Brain Biotech AG hat Sven K. Weber zum 1. Oktober 2026 für drei Jahre zum neuen Vorstandsvorsitzenden bestellt. Der 44-Jährige war seit 2011 in verschiedenen Führungspositionen... ► Artikel lesen | |
| VIVOSIM LABS | 0,323 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,191 | -6,83 % | Pharma- und Biotech-Aktien im Fokus mit Moderna, BioNxt Solutions und Eli Lilly! | Viele Patente der großen Pharmariesen laufen in den kommenden Jahren aus. Wenn der Schutz weg ist, dann drohen Umsatzeinbußen durch Nachahmer-Medikamente, die sogenannten Generika. Entsprechend hoch... ► Artikel lesen | |
| BAVARIAN NORDIC | 24,940 | +0,24 % | Bavarian Nordic A/S: Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years | MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN's position in... ► Artikel lesen |
Das Unternehmen EXPRES2ION BIOTECH HOLDING AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,98 % bei einem Aktienkurs von 0,101 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXPRES2ION BIOTECH HOLDING AB finden Sie auf Wallstreet Online.